| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-826 | |
| Phytochemical name or plant extracts | Halofuginone | |
| PMID | 24173318 | |
| Literature evidence | Taken together, these are the first results indicating that halofuginone may represent a promising new agent for breast cancer chemotherapy. | |
| IUPAC name | 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Dichroa febrifuga | |
| Geographical availability | Borneo, Cambodia, China North-Central, China South-Central, China Southeast, Jawa, Laos, Lesser Sunda Is., Malaya, Myanmar, New Guinea, Philippines, Sulawesi, Taiwan, Thailand, Tibet, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | MMP9 | |
| Gene or Protein evidence | Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. | |
| Target pathways | TGF-β/BMP signaling | |
| IC50 | At 48 h; 200 nM against MCF-7 | |
| Potency | Thus, halofuginone reduces breast and prostate cancer bone metastases in mice and combined with treatment currently approved by the FDA is an effective treatment for this devastating complication of breast and prostate-cancer. | |
| Cell line/ mice model | MDA-MB-231, PC3 | |
| Additional information | Halofuginone is a plant alkaloid-derivative with antiangiogenic and antiproliferative effects. | |
| PubChem ID | 400772 | |
| Additional PMIDs | 24173318 29156807 22885662 31046771 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:790930-1 | |
| Safety | NA |